(Q35544312)

8 August 2017

title

Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders (English)

1 reference

8 August 2017

author

Alexander Hapfelmeier

4

object named as

Alexander Hapfelmeier

1 reference

8 August 2017

5

Tania Kümpfel

1 reference

8 August 2017

Klaus Lehmann-Horn

1

1 reference

8 August 2017

Eva Schleich

2

1 reference

8 August 2017

Deetje Hertzenberg

3

1 reference

8 August 2017

Nikolas von Bubnoff

6

1 reference

8 August 2017

Reinhard Hohlfeld

7

1 reference

8 August 2017

Achim Berthele

8

1 reference

8 August 2017

Bernhard Hemmer

9

1 reference

8 August 2017

Martin S Weber

10

1 reference

8 August 2017

publication date

26 October 2011

1 reference

Journal of Neuroinflammation

8 August 2017

published in

1 reference

8 August 2017

volume

8

1 reference

8 August 2017

page(s)

146

1 reference

https://scigraph.springernature.com/pub.10.1186/1742-2094-8-146

8 August 2017

exact match

0 references

cites work

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Regulatory B cells in autoimmunity: developments and controversies.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

B cells regulate autoimmunity by provision of IL-10.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-gamma production

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce "oligoclonal bands".

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Worsening after rituximab treatment in anti-mag neuropathy

26 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1742-2094-8-146

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214191

Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies

26 September 2018

1 reference

12 December 2020

Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease)

1 reference

12 December 2020

Relapses After Treatment With Rituximab in a Patient With Multiple Sclerosis and Anti–Myelin-Associated Glycoprotein Polyneuropathy

1 reference

12 December 2020

Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease

1 reference

12 December 2020

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab

1 reference

12 December 2020

Identifiers

DOI

10.1186/1742-2094-8-146

1 reference

Dimensions Publication ID

8 August 2017

0 references

1 reference

8 August 2017

1 reference